Cardioselective β-adrenergic blocker. Antihypertensive, antianginal, antiarrhythmic. S-enantiomer (Cat. No. 0393) also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 25 mM in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 266.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.75 mL||18.77 mL||37.55 mL|
|5 mM||0.75 mL||3.75 mL||7.51 mL|
|10 mM||0.38 mL||1.88 mL||3.75 mL|
|50 mM||0.08 mL||0.38 mL||0.75 mL|
References are publications that support the products' biological activity.
Kahonen et al (1994) Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats. Br.J.Pharmacol. 112 925 PMID: 7921622
If you know of a relevant reference for (RS)-Atenolol, please let us know.
View Related Products by Product Action
Keywords: (RS)-Atenolol, supplier, β1-adrenoceptors, α1-adrenoceptor, beta1-adrenoceptors, antagonists, b-Adrenergic, β1-Adrenergic, beta1-Adrenergic, Receptors, b1-adrenoceptors, Adrenergic, Beta-1, Receptors, Adrenergic, Beta-1, Receptors, Tocris Bioscience
1 Citation for (RS)-Atenolol
Citations are publications that use Tocris products. Selected citations for (RS)-Atenolol include:
Sood et al (2010) Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120 1515 PMID: 20389021
Do you know of a great paper that uses (RS)-Atenolol from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.